ICU Medical (ICUI)
(Delayed Data from NSDQ)
$179.20 USD
+2.28 (1.29%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $179.39 +0.19 (0.11%) 7:58 PM ET
2-Buy of 5 2
B Value C Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$179.20 USD
+2.28 (1.29%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $179.39 +0.19 (0.11%) 7:58 PM ET
2-Buy of 5 2
B Value C Growth C Momentum B VGM
Zacks News
ICU Medical (ICUI) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
ICU Medical (ICUI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Match Group (MTCH) to Report Q3 Earnings: Is a Beat in Store?
by Zacks Equity Research
Match Group (MTCH) boasts of a robust product portfolio comprising Tinder, Match.com, Meetic, PlentyOfFish and OkCupid.
Can R&D Focus Drive DENTSPLY SIRONA's (XRAY) Q3 Earnings?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) focus on R&D and strategic buyouts to drive Q2 results.
Why the Earnings Surprise Streak Could Continue for ICU Medical (ICUI)
by Zacks Equity Research
ICU Medical (ICUI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Orthofix (OFIX) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Orthofix (OFIX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
TG Therapeutics (TGTX) in Focus: Stock Moves 8.6% Higher
by Zacks Equity Research
TG Therapeutics (TGTX) shares rose nearly 9% in the last trading session, amid huge volumes.
ICU Medical (ICUI) Enters Oversold Territory
by Zacks Equity Research
ICU Medical, Inc. (ICUI) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
3 Top Stocks From the Booming US Medical Products Industry
by Sreyoshi Mukherjee
The U.S. Medical Products industry is sturdy on solid focus on technological advancement.
Medical - Products Stock Outlook: Short-Term Pain Inevitable
by Zacks Equity Research
Near-term growth prospects of medical products are being questioned due to trade war apprehensions and President Trump's imposition of fresh tariffs on about $200 billion on Chinese imports.
Baxter's Actifuse Flow Bone Graft Substitute Gets FDA Nod
by Zacks Equity Research
The latest FDA approval for Baxter's (BAX) Actifuse Flow bone graft is likely to boost its Advanced Surgery segment.
Why ICU Medical (ICUI) Might be Well Poised for a Surge
by Zacks Equity Research
ICU Medical (ICUI) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Zacks.com featured highlights include: ICU Medical, FTI, Aspen, Old Dominion and Illumina
by Zacks Equity Research
Zacks.com featured highlights include: ICU Medical, FTI, Aspen, Old Dominion and Illumina
5 Momentum Stocks Worth Investing in via Driehaus Strategy
by Zacks Equity Research
Using the "buy high and sell higher" rule, Richard Herman Driehaus has created an investment approach.
ICU Medical (ICUI) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
ICU Medical (ICUI) delivered earnings and revenue surprises of 45.36% and 7.22%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Is ICU Medical (ICUI) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is ICU Medical, Inc. (ICUI) Outperforming Other Medical Stocks This Year?
Zacks.com highlights: Medifast, Myriad Genetics, ICU Medical, Ellie Mae and UGI
by Zacks Equity Research
Zacks.com highlights: Medifast, Myriad Genetics, ICU Medical, Ellie Mae and UGI
Shrug Off Market Volatility With These 5 Low Beta Stocks
by Zacks Equity Research
We develop a strategy that clearly shows that less risky stocks have the potential to reward shareholders with impressive returns only when certain parameters are considered.
LeMaitre Vascular (LMAT) Soars to a 52-Week High, Time to Cash Out?
by Zacks Equity Research
LeMaitre Vascular, Inc. is at a 52-week high, but can investors hope for more gains in the future? We take a look at the fundamentals for LMAT for clues.
Zacks.com featured highlights include: ICU Medical, KAR Auction, Sony, Goldman Sachs and United Natural
by Zacks Equity Research
Zacks.com featured highlights include: ICU Medical, KAR Auction, Sony, Goldman Sachs and United Natural
Rely on Driehaus Strategy and Buy These 5 Momentum Stocks
by Zacks Equity Research
Investors with high risk-tolerance can invest in momentum stocks using Driehaus Strategy.
Zacks.com highlights: Stamps.com, ICU Medical, LeMaitre Vascular, United States Cellular and Everest Re Group
by Zacks Equity Research
Zacks.com highlights: Stamps.com, ICU Medical, LeMaitre Vascular, United States Cellular and Everest Re Group
Boost Immunity to Market Volatility With 5 Low-Beta Stocks
by Zacks Equity Research
We have developed a strategy which clearly shows that stocks with low risk could also reward investors with handsome returns.
ICU Medical (ICUI) Hits a 52-Week-High, Can the Run Continue?
by Zacks Equity Research
ICU Medical, Inc. is at a 52-week high, but can investors hope for more gains in the future? We take a look at the fundamentals for ICUI for clues.
Fresenius Medical (FMS) Q4 Earnings Beat, View Impressive
by Nabaparna Bhattacharya
Higher sales of dialyzers, machines, peritoneal dialysis products, renal pharmaceuticals, bloodlines and products for acute care boost Fresenius Medical (FMS) in Q4.
Here's Why You Should Invest in Bio-Rad (BIO) Right Now
by Zacks Equity Research
Positive tidings on the regulatory front and strong fourth-quarter performance boost investors' confidence in Bio-Rad (BIO).